New osteoporosis medication fails in clinical trial

In recent years, there have been a number of new medications tested that have sought to become the standard for osteoporosis treatment and to replace a prescription to buy Fosamax as the leading drug for preserving bone strength. However, the vast majority of these new drugs have failed.

The latest in the line of poorly performing drugs is an oral medication being tested by the pharmaceutical company Novartis and Unigene Laboratories. In a recent phase 3 trial, the new osteoporosis medication failed to deliver any actual benefit compared to a placebo.

Representatives of Unigene said that the findings would not stop them from pursuing approval of the medication. Further studies could prove it to be an effective alternative to currently available drugs. However, this will at least delay the new prescription from gaining approval and wider acceptance.

For the time being, the failure of the clinical trial sures up the position of Fosamax as one of the leading therapies for strengthening bones and preventing the development of osteoporosis. Women who are at risk for the brittle bone disease may benefit from talking to their doctor about a prescription to buy Fosamax.